B₆ and Bleeding: A Case Report of a Novel Vitamin Toxicity

Area of Science:

• Biochemistry
• Metabolic Disorders
• Genetics

Background:

• Pyridox(am)ine-5-phosphate oxidase deficiency is a rare genetic disorder affecting vitamin B6 metabolism.
• It necessitates continuous treatment with pyridoxal-5-phosphate to manage severe neonatal seizures.
• Vitamin B6 (pyridoxine and its active forms) is crucial for numerous enzymatic reactions.

Observation:

• A patient with pyridox(am)ine-5-phosphate oxidase deficiency and mild hemophilia A was treated with pyridoxal-5-phosphate.
• The essential vitamin B6 therapy led to an exacerbation of the patient's bleeding symptoms.
• This presented a complex clinical challenge balancing seizure control and bleeding risk.

Findings:

• The study details the first reported case of vitamin B6 therapy exacerbating bleeding in a patient with pyridox(am)ine-5-phosphate oxidase deficiency and hemophilia A.
• This observation expands the understanding of potential adverse effects and toxicity associated with vitamin B6 supplementation.
• The findings underscore a previously unrecognized interaction between vitamin B6 therapy and coagulation in specific patient populations.

Implications:

• Clinicians must be vigilant for increased bleeding risks in patients with underlying coagulation disorders receiving pyridoxine or pyridoxal-5-phosphate.
• This case highlights the need for careful monitoring and potential dose adjustments of vitamin B6 therapy in such patients.
• Further research is warranted to elucidate the mechanisms behind vitamin B6-induced bleeding exacerbation and to establish safer therapeutic guidelines.